. Author manuscript; available in PMC: 2017 Jun 15.

Published in final edited form as: J Immunol. 2016 May 18;196(12):5036–5046. doi: 10.4049/jimmunol.1501973

Table I.

. Percent BTLA⁺ Tregs following treatment of EAE mice with PBS, OVA-pσ1, or MOG-pσ1

	%BTLA⁺ Foxp3⁺ CD25⁺ CD4⁺ T cells^b		%BTLA⁺ CD25⁻ CD4⁺ T cells^b

Treatment Group^a	Mean ±SEM	p-value^c	Mean ± SEM	p-value^c
Naive (no EAE)	17.52 ± 0.79	NS	9.07 ± 2.08	NS
PBS-treated EAE	26.40 ± 5.64	-	13.22 ± 3.29	-
OVA-pσ1- treated EAE	27.86 ±8.61	NS	14.15 ±5.90	NS
MOG-pσ1- treated EAE	30.72 ± 4.95	NS	18.40 ± 5.99	NS

C57BL/6 mice were induced with EAE, and treated with PBS or 50 μg of OVA-pσ1 or MOG-pσ1 orally at the peak of EAE.

FACS analysis was performed on BTLA⁺ Tregs and CD25 CD4⁺ T cells isolated from the spleen. Mean ± SEM of 5-6 mice per group is presented.

Statistical significance was calculated by the one-way ANOVA to test differences among the treatment groups relative to PBS-treated EAE mice; NS = not significant.